In this episode of Subro on the Go, regular co-hosts, David Brisco (San Diego) and Joe Rich (Miami) are joined by Joseph Duque (San Diego) to commence our Back to Basic series. In 2026 we are covering the key steps
Oregon House Bill 3746, which became law on July 24, 2025 and became effective on January 1, 2026, operates to shorten the statute of repose for “a tort action by a homeowners association or association of unit owners arising from
As part of Florida’s March 2023 tort and insurance reforms, the Florida legislature introduced a safe harbor for carriers to avoid bad faith liability in claims involving multiple third party claimants. The provision appears in Fla. Stat. 624.155(6) and states
As part of OSHA’s efforts to enhance compliance assistance, it launched its “Safety Champions Program” (SCP) effective February 24, 2026. SCP is a new program for employers to develop and implement an effective safety and health program. The SCP incorporates
On February 23, the FDA announced a new approval pathway designed to support the development of drugs for ultra-rare diseases. Often, treatments for ultra-rare diseases have difficulty meeting the agency’s rigorous approval requirements. The FDA has issued a guidance document
In the recent decision of StarStone National Insurance Company v. Golf Argonomics Supply & Handling Co., 2026 WL 245860 (M.D. Fla. Jan. 10, 2026), the Court granted StarStone’s motion for judgment on the pleadings ruling that a broader automobile exclusion
The Indiana Supreme Court’s decision in Baldwin v. Standard Fire Ins. Co., 269 N.E.3d 1197 (Ind. 2025) provides clarity for insurers confronted with competing claims that exceed policy limits. In a matter of first impression, the Court held that declining
When pursuing a subrogation claim for property damages against a public entity, the claimant carrier must evaluate its potential causes of action (i.e., theories of liability). Two common tort actions, with their differences often misunderstood, are inverse condemnation and negligence.
The FDA recently shared information regarding its flexible approach to overseeing chemistry, manufacturing, and control (CMC) requirements for cell and gene therapies (CGT). Due to the unique nature of the characteristics of CGT, regulatory flexibility must be adapted in a
